tradingkey.logo
tradingkey.logo
Search

China's Xuanzhu Biopharmaceutical Soars 158% in Hong Kong Grey Market

TigerOct 14, 2025 8:15 AM
facebooktwitterlinkedin
View all comments(0)

Xuanzhu Biopharmaceutical, which is being spun off from China's Sihuan Pharmaceutical, soared 158% in Hong Kong grey market.

Last year, the company expanded its net loss by 85.1 percent to 556.4 million yuan (HK$608.3 million), while its revenue surged 1036.7 times to 30.1 million yuan from its core product KBP-3571 for digestive diseases during the period.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.